Stock TRVI TREVI THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Trevi Therapeutics, Inc.

Equities

TRVI

US89532M1018

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
2.65 USD -7.02% Intraday chart for Trevi Therapeutics, Inc. +2.71% +97.76%
Mar. 20 Transcript : Trevi Therapeutics, Inc., Q4 2023 Earnings Call, Mar 20, 2024
Mar. 20 Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
AQ
Trevi Therapeutics to Participate in Upcoming April Events
PR
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
PR
Transcript : Trevi Therapeutics, Inc., Q4 2023 Earnings Call, Mar 20, 2024
Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Trevi Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
PR
Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024
PR
Trevi Therapeutics to Participate in Upcoming March Events
PR
Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
PR
Trevi Therapeutics Provides Business Updates
PR
Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio for Chronic Cough in Idiopathic Pulmonary Fibrosis
AQ
Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)
PR
Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio? for Chronic Cough in Idiopathic Pulmonary Fibrosis
CI
Transcript : Trevi Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Trevi Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update
PR
Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio for Refractory Chronic Cough
AQ
Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough
PR
Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio?? for Refractory Chronic Cough
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRVI Stock
  4. News Trevi Therapeutics, Inc.